The Impact of Statin and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults with Human Immunodeficiency Virus Infection

Clinical Infectious Diseases

Volumn 65, Issue 12, 2017, Pages 2042-2049

  Erlandson, Kristine M ^a   Kitch, Douglas ^b   Wester, C William ^c   Kalayjian, Robert C ^d   Overton, Edgar Turner ^e   Castillo Mancilla, Jose ^a   Koletar, Susan L ^f   Benson, Constance A ^g   Campbell, Thomas B ^a   Robertson, Kevin ^h   Lok, Judith J ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d METROHEALTH MEDICAL CENTER   (United States)

^e UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^f THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Angiotensin Receptor Antagonists; Angiotensin Converting Enzyme Inhibitors; HIV; Hydroxymethylglutaryl CoA Reductase Inhibitors (statins); neurocognitive disorders

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIRETROVIRUS AGENT; ATORVASTATIN; BENAZAPRIL; CADESARTAN; CAPTOPRIL; CERVISTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALOPRIL; FLUINDOSTATIN; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; OLMESARTAN; PRAVASTATIN; QUINAPRIL; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; TELMISARTAN; UNCLASSIFIED DRUG; VALSARTAN; VIRUS RNA;

ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CEREBROVASCULAR DISEASE; CHOLESTEROL LEVEL; CLINICAL EVALUATION; CLINICAL OUTCOME; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISORDERS OF HIGHER CEREBRAL FUNCTION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; HOPKINS VERBAL LEARNING TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROLOGIC DISEASE ASSESSMENT; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SMOKING; SYSTOLIC BLOOD PRESSURE; URINE SAMPLING; AGED; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; HUMAN IMMUNODEFICIENCY VIRUS; VIROLOGY;

ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COGNITION; COHORT STUDIES; FEMALE; HIV; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROCOGNITIVE DISORDERS;

EID: 85040041467     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix645     Document Type: Article

References (39)

1. McArthur JC. HIV dementia: an evolving disease. J Neuroimmunol 2004; 157:3-10.
2. McMurtray A, Nakamoto B, Shikuma C, Valcour V. Small-vessel vascular disease in human immunodeficiency virus infection: the Hawaii aging with HIV cohort study. Cerebrovasc Dis 2007; 24:236-41.
3. McMurtray A, Nakamoto B, Shikuma C, Valcour V. Cortical atrophy and white matter hyperintensities in HIV: the Hawaii aging with HIV cohort study. J Stroke Cerebrovasc Dis 2008; 17:212-7.
4. Barzilay JI, Fitzpatrick AL, Luchsinger J, et al. Albuminuria and dementia in the elderly: a community study. Am J Kidney Dis 2008; 52:216-26.
5. Jassal SK, Kritz-Silverstein D, Barrett-Connor E. A prospective study of albuminuria and cognitive function in older adults: the Rancho Bernardo study. Am J Epidemiol 2010; 171:277-86.
6. Joosten H, Izaks GJ, Slaets JP, et al. Association of cognitive function with albuminuria and eGFR in the general population. Clin J Am Soc Nephrol 2011; 6:1400-9.
7. Vupputuri S, Shoham DA, Hogan SL, Kshirsagar AV. Microalbuminuria, peripheral artery disease, and cognitive function. Kidney Int 2008; 73:341-6.
8. Weiner DE, Bartolomei K, Scott T, et al. Albuminuria, cognitive functioning, and white matter hyperintensities in homebound elders. Am J Kidney Dis 2009; 53:438-47.
9. Kalayjian RC, Wu K, Evans S, et al. Proteinuria is associated with neurocognitive impairment in antiretroviral therapy treated HIV-infected individuals. J Acquir Immune Defic Syndr 2014; 67:30-5.
10. Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol 2012; 60:875-81.
11. Padala KP, Padala PR, McNeilly DP, Geske JA, Sullivan DH, Potter JF. The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer's dementia: a prospective withdrawal and rechallenge pilot study. Am J Geriatr Pharmacother 2012; 10:296-302.
12. King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 2003; 23:1663-7.
13. Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy 2001; 21:767-9.
14. Padala KP, Padala PR, Potter JF. Statins: a case for drug withdrawal in patients with dementia. J Am Geriatr Soc 2010; 58:1214-6.
15. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003; 23:871-80.
16. US Department of Health and Human Services. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. 28 February 2012. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm. Accessed 4 November 2012.
17. Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch Neurol 2011; 68:1385-92.
18. Ancelin ML, Carriere I, Barberger-Gateau P, et al. Lipid lowering agents, cognitive decline, and dementia: the three-city study. J Alzheimers Dis 2012; 30:629-37.
19. Sano M, Bell KL, Galasko D, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 2011; 77:556-63.
20. Shepherd J, Blauw GJ, Murphy MB, et al; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360:1623-30.
21. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev 2016;1:CD003160.
22. Swiger KJ, Martin SS, Tang F, et al. Cognitive and physical function by statin exposure in elderly individuals following acute myocardial infarction. Clin Cardiol 2015; 38:455-61.
23. Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS. Statins and cognition: a systematic review and meta-analysis of short-and long-term cognitive effects. Mayo Clin Proc 2013; 88:1213-21.
24. Ott BR, Daiello LA, Dahabreh IJ, et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med 2015; 30:348-58.
25. Letendre SL, Marquie-Beck J, Ellis RJ, et al; CHARTER Group. The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. J Neuroimmune Pharmacol 2007; 2:120-7.
26. Barzilay JI, Gao P, O'Donnell M, et al; ONTARGET and TRANSCEND Investigators. Albuminuria and decline in cognitive function: the ONTARGET/TRANSCEND studies. Arch Intern Med 2011; 171:142-50.
27. Smurzynski M, Collier AC, Koletar SL, et al. AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics. HIV Clin Trials 2008; 9:269-82.
28. Heaton RK, Heaton RK, Psychological assessment resources I. Revised comprehensive norms for an expanded Halstead-Reitan battery: demographically adjusted neuropsychological norms for African American and Caucasian adults, professional manual. Lutz, FL.: Psychological Assessment Resources, 2004.
29. Brandt J, Benedict RHB. Hopkins Verbal Learning Test-Revised. Administration manual. Lutz, FL: Psychological Assessment Resources, 2001.
30. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11:550-60.
31. Iantorno M, Schar M, Soleimanifard S, et al. Coronary artery endothelial dysfunction is present in HIV-positive individuals without significant coronary artery disease. AIDS 2017; 31:1281-9.
32. Eden A, Marcotte TD, Heaton RK, et al. Increased intrathecal immune activation in virally suppressed HIV-1 infected patients with neurocognitive impairment. PLoS One 2016; 11:e0157160.
33. Cibičkova L. Statins and their influence on brain cholesterol. J Clin Lipidol 2011; 5:373-9.
34. Lutjohann D, Stroick M, Bertsch T, et al. High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids 2004; 69:431-8.
35. Ogawa S, Kobori H, Ohashi N, et al. Angiotensin II type 1 receptor blockers reduce urinary angiotensinogen excretion and the levels of urinary markers of oxidative stress and inflammation in patients with type 2 diabetic nephropathy. Biomark Insights 2009; 4:97-102.
36. Reynaert NL, Gopal P, Rutten EP, Wouters EF, Schalkwijk CG. Advanced glycation end products and their receptor in age-related, non-communicable chronic inflammatory diseases; overview of clinical evidence and potential contributions to disease. Int J Biochem Cell Biol 2016; 81:403-18.
37. Bangalore S, Fakheri R, Wandel S, Toklu B, Wandel J, Messerli FH. Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. BMJ 2017; 356:j4.
38. Gansevoort RT, Matsushita K, van der Velde M, et al; Chronic Kidney Disease Prognosis Consortium. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes: a collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 2011; 80:93-104.
39. Choi A, Scherzer R, Bacchetti P, et al. Cystatin C, albuminuria, and 5-year allcause mortality in HIV-infected persons. Am J Kidney Dis 2010; 56:872-82.